You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Reproducible glioblastoma drug study on GDSC screens (20,329 dose-response curves, 542 compounds, 34 GBM lines): which compounds are GBM-selective, whether structure predicts response (descriptors, fingerprints, GNNs on scaffold-disjoint folds vs null baselines), and which pairs merit combination screens.
PERSIST (PERsister-State In-Silico Targeting): residual-state modelling of single-cell drug response for combination therapy prediction in EGFR-mutant NSCLC and TNBC